Challenges in clinical trials for high-risk but curable prostate cancer

被引：1
|
作者：
Dorff, Tanya Barauskas [1 ,3 ]
Bryce, Alan H. [2 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[2] City Hope Phoenix, Dept Med Oncol & Therapeut Res, Phoenix, AZ USA
[3] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, 1500 E Duarte Rd, PAV2250, Duarte, CA 91010 USA
来源：
CANCER | 2024年 / 130卷 / 09期
关键词：
androgen-deprivation therapy; clinical trial recruitment and retention; patient advocate; prostate cancer; prostatectomy;
D O I：
10.1002/cncr.35245
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Clinical trials studying neoadjuvant and adjuvant therapy around prostatectomy for patients with high-risk prostate cancer have faced multiple challenges. Patients who have a very good response to neoadjuvant therapy may not wish to continue to adjuvant treatment, and prostate-specific antigen-based end points are difficult to interpret because of variations in testosterone recovery.
引用
收藏
页码：1575 / 1576
页数：2
相关论文
共 50 条
  • [21] LONG-TERM RESULTS AFTER HIGH-DOSE RADIOTHERAPY AND ADJUVANT HORMONES IN PROSTATE CANCER: HOW CURABLE IS HIGH-RISK DISEASE?
    Zapatero, Almudena
    Garcia-Vicente, Feliciano
    Martin de Vidales, Carmen
    Cruz Conde, Alfonso
    Ibanez, Yamile
    Fernandez, Inmaculada
    Rabadan, Mariano
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (05): : 1279 - 1285
  • [22] Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
    Clark, Roderick
    Herrera-Caceres, Jaime
    Kenk, Miran
    Fleshner, Neil
    CANCERS, 2022, 14 (04)
  • [23] The Role of Robot-Assisted Radical Prostatectomy in High-Risk Prostate Cancer
    Srougi, Victor
    Tourinho-Barbosa, Rafael R.
    Nunes-Silva, Igor
    Baghdadi, Mohammed
    Garcia-Barreras, Silvia
    Rembeyo, Gregory
    Eiffel, Sophie S.
    Barret, Eric
    Rozet, Francois
    Galiano, Marc
    Sanchez-Salas, Rafael
    Cathelineau, Xavier
    JOURNAL OF ENDOUROLOGY, 2017, 31 (03) : 229 - 237
  • [24] Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology
    Baboudjian, M.
    Beauval, J-B
    Barret, E.
    Brureau, L.
    Crehange, G.
    Dariane, C.
    Fiard, G.
    Fromont, G.
    Gauthe, M.
    Mathieu, R.
    Renard-Penna, R.
    Roubaud, G.
    Ruffion, A.
    Sargos, P.
    Roupret, M.
    Ploussard, G.
    PROGRES EN UROLOGIE, 2022, 32 (10): : 623 - 634
  • [25] High-Risk Prostate Cancer: From Definition to Contemporary Management
    Bastian, Patrick J.
    Boorjian, Stephen A.
    Bossi, Alberto
    Briganti, Alberto
    Heidenreich, Axel
    Freedland, Stephen J.
    Montorsi, Francesco
    Roach, Mack, III
    Schroder, Fritz
    van Poppel, Hein
    Stief, Christian G.
    Stephenson, Andrew J.
    Zelefsky, Michael J.
    EUROPEAN UROLOGY, 2012, 61 (06) : 1096 - 1106
  • [26] Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer
    Nakabayashi M.
    Oh W.K.
    Current Treatment Options in Oncology, 2004, 5 (5) : 349 - 355
  • [27] Controversies in the therapy of high-risk prostate cancer. Radiotherapy
    Boehmer, D.
    ONKOLOGE, 2015, 21 (09): : 805 - +
  • [28] Controversies in the therapy of high-risk prostate cancer. Radiotherapy
    Boehmer, D.
    ONKOLOGE, 2015, 21 (09): : 805 - +
  • [29] The multi-disciplinary management of high-risk prostate cancer
    Picard, Jonathan C.
    Golshayan, Ali-Reza
    Marshall, David T.
    Opfermann, Krisha J.
    Keane, Thomas E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (01) : 3 - 15
  • [30] Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective
    Stewart, Suzanne B.
    Boorjian, Stephen A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (05) : 235 - 244
12345